NASDAQ: COGT
Cogent Biosciences Inc Stock

$28.56-0.58 (-1.99%)
Updated Nov 13, 2026
COGT Price
$28.56
Fair Value Price
$0.37
Market Cap
$4.97B
52 Week Low
$27.74
52 Week High
$43.73
P/E
-12.69x
P/B
9.63x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$407.68M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.61
Operating Cash Flow
-$324M
Beta
1.22
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

COGT Overview

Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine COGT's potential to beat the market

DSell
  • Stocks with a Zen Rating of Sell (D) had an average loss of -6.47% per year. Learn More

Zen Rating Component Grades

D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
COGT
Ranked
#383 of 450

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important COGT news, forecast changes, insider trades & much more!

COGT News

Overview

Due Diligence Score

–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how COGT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

COGT ($28.56) is overvalued by 7,711.06% relative to our estimate of its Fair Value price of $0.37 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
COGT ($28.56) is not significantly undervalued (7,711.06%) relative to our estimate of its Fair Value price of $0.37 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
COGT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more COGT due diligence checks available for Premium users.

Valuation

COGT fair value

Fair Value of COGT stock based on Discounted Cash Flow (DCF)

Price
$28.56
Fair Value
$0.37
Overvalued by
7,711.06%
COGT ($28.56) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
COGT ($28.56) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
COGT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

COGT price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-12.69x
Industry
18.56x
Market
41.11x

COGT price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
9.63x
Industry
5.14x
COGT is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

COGT's financial health

Profit margin

Revenue
$0.0
Net Income
-$111.4M
Profit Margin
0%
COGT's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$832.1M
Liabilities
$315.9M
Debt to equity
0.61
COGT's short-term assets ($803.58M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
COGT's short-term assets ($803.58M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
COGT's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
COGT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$80.8M
Investing
$37.3M
Financing
$79.8M
COGT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

COGT vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
COGTD$4.97B-1.99%-12.69x9.63x
EWTXC$5.03B+0.24%4.97x3.08x
TVTXC$4.86B-1.76%-39.26x215.29x
IONSC$4.84B+6.41%-8.70x12.29x
DNTHC$5.17B-0.72%-22.50x4.16x

Cogent Biosciences Stock FAQ

What is Cogent Biosciences's quote symbol?

(NASDAQ: COGT) Cogent Biosciences trades on the NASDAQ under the ticker symbol COGT. Cogent Biosciences stock quotes can also be displayed as NASDAQ: COGT.

If you're new to stock investing, here's how to buy Cogent Biosciences stock.

What is the 52 week high and low for Cogent Biosciences (NASDAQ: COGT)?

(NASDAQ: COGT) Cogent Biosciences's 52-week high was $43.73, and its 52-week low was $27.74. It is currently -34.69% from its 52-week high and 2.97% from its 52-week low.

How much is Cogent Biosciences stock worth today?

(NASDAQ: COGT) Cogent Biosciences currently has 173,994,452 outstanding shares. With Cogent Biosciences stock trading at $28.56 per share, the total value of Cogent Biosciences stock (market capitalization) is $4.97B.

Cogent Biosciences stock was originally listed at a price of $44.44 in Mar 29, 2018. If you had invested in Cogent Biosciences stock at $44.44, your return over the last 8 years would have been -35.73%, for an annualized return of -5.38% (not including any dividends or dividend reinvestments).

How much is Cogent Biosciences's stock price per share?

(NASDAQ: COGT) Cogent Biosciences stock price per share is $28.56 today (as of Nov 13, 2026).

What is Cogent Biosciences's Market Cap?

(NASDAQ: COGT) Cogent Biosciences's market cap is $4.97B, as of Nov 16, 2026.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Cogent Biosciences's market cap is calculated by multiplying COGT's current stock price of $28.56 by COGT's total outstanding shares of 173,994,452.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.